ANIK
Anika Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$20.22
+1.20%Year over year
Reported trailing growth
- Revenue
- +31.4%
- EBITDA
- +173.1%
- EBIT
- +40.9%
- EPS
- +93.5%
- Free cash flow
- +149.5%
- Operating cash flow
- -4.8%
Forward estimates
Based on analyst estimates
- Revenue
- +3.7%
- EBITDA
- +898.3%
- EPS
- +448.8%
Three-year CAGR
- Revenue
- -0.3%
- EBITDA
- —
- EBIT
- —
- Net income
- +80.7%
- EPS
- +80.2%
- Free cash flow
- +287.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026